Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up to $4.86

Shares of Autolus Therapeutics plc (NASDAQ:AUTL) gapped up before the market opened on Wednesday . The stock had previously closed at $4.86, but opened at $5.10. Autolus Therapeutics shares last traded at $4.88, with a volume of 43,610 shares.

Analysts Set New Price Targets

A number of equities analysts have issued reports on AUTL shares. Truist Financial lifted their target price on shares of Autolus Therapeutics from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, April 9th. Needham & Company LLC reaffirmed a “buy” rating and set a $9.00 price target on shares of Autolus Therapeutics in a research report on Friday, April 12th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $8.16.

Autolus Therapeutics Price Performance

The stock’s 50-day moving average is $5.98 and its 200-day moving average is $5.08.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings results on Thursday, March 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.18). On average, equities analysts forecast that Autolus Therapeutics plc will post -0.71 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets boosted its stake in Autolus Therapeutics by 337.3% during the fourth quarter. BNP Paribas Financial Markets now owns 4,268 shares of the company’s stock worth $27,000 after buying an additional 3,292 shares in the last quarter. Renaissance Technologies LLC acquired a new position in Autolus Therapeutics during the 2nd quarter valued at about $36,000. Two Sigma Advisers LP bought a new stake in shares of Autolus Therapeutics in the 1st quarter valued at about $25,000. Jane Street Group LLC bought a new stake in shares of Autolus Therapeutics in the 2nd quarter valued at about $42,000. Finally, CI Private Wealth LLC bought a new stake in shares of Autolus Therapeutics in the 4th quarter valued at about $28,000. Institutional investors and hedge funds own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.